Hepatitis B Virus Reactivation in COVID-19

The aim of this observational cohort study was to evaluate adherence to hepatitis B virus (HBV) screening guidelines in a country characterized by low HBV prevalence and assess the potential reactivation and progression of HBV infection in anti-HBV core antigen antibodies (anti-HBc) positive patients receiving corticosteroids for coronavirus disease 2019 (COVID-19).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Pneumonia Blood-Borne Infections Communicable Diseases DNA Virus Infections Digestive System Diseases Hepadnaviridae Infections Hepatitis Hepatitis B Hepatitis, Viral, Human Hypoxemia Hypoxia Infections Liver Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Respiratory Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Medical Centre Ljubljana

Ljubljana, Slovenia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

hospitalized adult patients with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ribonucleic acid (RNA) polymerase chain reaction (PCR) test
supplemental oxygen
treated with corticosteroids for COVID-19 pneumonia

Exclusion criteria

age under 18 years
hospitalized for medical conditions unrelated to COVID-19
received corticosteroid therapy for non-COVID-19 reasons

Treatment and study plan

Hepatitis B virus infection

Diagnostic Test

anti-hepatitis B virus core antigen positive serologic status

Primary outcomes

HBV reactivation

Time frame: at least 3 months post treatment with corticosteroids

number (%) of patients with HBV reactivation
number (%) of patients with HBV reactivation

Time frame: one year

Sponsors and collaborators

Lead sponsor

University Medical Centre Ljubljana

Other

Registry information

Official study title

Managing the Risk of Hepatitis B Virus Reactivation in COVID-19 Patients Treated With Corticosteroids

Acronym: HBV-C19

Important dates

Study start: 2020
Primary completion: 2022
Study completion: 2022
First posted: Sep 4, 2025
Registry last updated: Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed